Literature DB >> 34375690

Nanomedicine based approaches for combating viral infections.

Saurabh Shah1, Mahavir Bhupal Chougule2, Arun K Kotha2, Rama Kashikar2, Chandraiah Godugu3, Rajeev Singh Raghuvanshi4, Shashi Bala Singh3, Saurabh Srivastava5.   

Abstract

Millions of people die each year from viral infections across the globe. There is an urgent need to overcome the existing gap and pitfalls of the current antiviral therapy which include increased dose and dosing frequency, bioavailability challenges, non-specificity, incidences of resistance and so on. These stumbling blocks could be effectively managed by the advent of nanomedicine. Current review emphasizes over an enhanced understanding of how different lipid, polymer and elemental based nanoformulations could be potentially and precisely used to bridle the said drawbacks in antiviral therapy. The dawn of nanotechnology meeting vaccine delivery, role of RNAi therapeutics in antiviral treatment regimen, various regulatory concerns towards clinical translation of nanomedicine along with current trends and implications including unexplored research avenues for advancing the current drug delivery have been discussed in detail.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral; RNAi; barriers; nanomedicine; nanovaccine

Mesh:

Substances:

Year:  2021        PMID: 34375690      PMCID: PMC8526416          DOI: 10.1016/j.jconrel.2021.08.011

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   11.467


  235 in total

1.  Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes.

Authors:  Jean-François Gagné; André Désormeaux; Sylvie Perron; Michel J Tremblay; Michel G Bergeron
Journal:  Biochim Biophys Acta       Date:  2002-02-01

2.  RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells.

Authors:  Paban Kumar Dash; Mugdha Tiwari; S R Santhosh; Manmohan Parida; P V Lakshmana Rao
Journal:  Biochem Biophys Res Commun       Date:  2008-09-19       Impact factor: 3.575

3.  Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients.

Authors:  Janet L Macpherson; Maureen P Boyd; Allison J Arndt; Alison V Todd; Gregory C Fanning; Julie A Ely; Fiona Elliott; Alison Knop; Mitch Raponi; John Murray; Wayne Gerlach; Lun-Quan Sun; Ronald Penny; Geoff P Symonds; Andrew Carr; David A Cooper
Journal:  J Gene Med       Date:  2005-05       Impact factor: 4.565

4.  Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection.

Authors:  Richard D Kensinger; Bradley J Catalone; Fred C Krebs; Brian Wigdahl; Cara-Lynne Schengrund
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

5.  Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro.

Authors:  Tathagata Dutta; Minakshi Garg; Narendra K Jain
Journal:  Eur J Pharm Sci       Date:  2008-04-18       Impact factor: 4.384

Review 6.  Dendrimers in the context of nanomedicine.

Authors:  Ana Paula Dias; Soraya da Silva Santos; João Vitor da Silva; Roberto Parise-Filho; Elizabeth Igne Ferreira; Omar El Seoud; Jeanine Giarolla
Journal:  Int J Pharm       Date:  2019-11-20       Impact factor: 5.875

7.  Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles.

Authors:  Yung-Chih Kuo; Fu-Lung Su
Journal:  Int J Pharm       Date:  2007-03-12       Impact factor: 5.875

8.  pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute.

Authors:  Sung-Up Choi; Tot Bui; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2008-02       Impact factor: 3.534

9.  Enhanced virus filtration in hybrid membranes with MWCNT nanocomposite.

Authors:  Zoltán Németh; Gergő Péter Szekeres; Mateusz Schabikowski; Krisztina Schrantz; Jacqueline Traber; Wouter Pronk; Klára Hernádi; Thomas Graule
Journal:  R Soc Open Sci       Date:  2019-01-09       Impact factor: 2.963

10.  A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice.

Authors:  Jing Lu; Guoliang Lu; Shudan Tan; Jia Xia; Hualong Xiong; Xiaofei Yu; Qingqing Qi; Xiang Yu; Li Li; Hang Yu; Ningshao Xia; Tianying Zhang; Yingjie Xu; Jinzhong Lin
Journal:  Cell Res       Date:  2020-08-17       Impact factor: 25.617

View more
  3 in total

Review 1.  Chitosan and its derivatives as polymeric anti-viral therapeutics and potential anti-SARS-CoV-2 nanomedicine.

Authors:  Rebecca Shu Ling Tan; Pouya Hassandarvish; Chin Fei Chee; Lai Wah Chan; Tin Wui Wong
Journal:  Carbohydr Polym       Date:  2022-04-20       Impact factor: 10.723

2.  In-vivo pharmacokinetic studies of Dolutegravir loaded spray dried Chitosan nanoparticles as milk admixture for paediatrics infected with HIV.

Authors:  Priya Dharshini K; Ramya Devi D; Banudevi S; Vedha Hari B Narayanan
Journal:  Sci Rep       Date:  2022-08-16       Impact factor: 4.996

3.  Nanoformulation Composed of Ellagic Acid and Functionalized Zinc Oxide Nanoparticles Inactivates DNA and RNA Viruses.

Authors:  Khaled AbouAitah; Abdou K Allayh; Jacek Wojnarowicz; Yasser M Shaker; Anna Swiderska-Sroda; Witold Lojkowski
Journal:  Pharmaceutics       Date:  2021-12-16       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.